Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Newly Diagnosed Multiple Myeloma (NDMM)”

40 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 40 results

Not applicableLooking for participantsNCT07087964
What this trial is testing

Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Newly Diagnosed Multiple Myeloma (NDMM)
Universiteit Antwerpen 120
Large-scale testing (Phase 3)Looking for participantsNCT05827016
What this trial is testing

Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 1,216
Testing effectiveness (Phase 2)Looking for participantsNCT07169500
What this trial is testing

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of Young NDMM

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 50
Not applicableStudy completedNCT02741544
What this trial is testing

Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

Who this might be right for
Multiple Myeloma
Celgene 578
Testing effectiveness (Phase 2)Study completedNCT02046070
What this trial is testing

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 148
Large-scale testing (Phase 3)Looking for participantsNCT06918002
What this trial is testing

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome 824
Early research (Phase 1)Study completedNCT04196491
What this trial is testing

Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 13
Large-scale testing (Phase 3)Looking for participantsNCT06879379
What this trial is testing

KPD Consolidation After ASCT in NDMM Patients

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Peking University People's Hospital 202
Large-scale testing (Phase 3)Study completedNCT02312258
What this trial is testing

Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Who this might be right for
Multiple Myeloma
Takeda 706
Not applicableLooking for participantsNCT07296627
What this trial is testing

Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Newly Diagnosed Multiple Myeloma (NDMM)
Peking University People's Hospital 500
Testing effectiveness (Phase 2)Looking for participantsNCT05850286
What this trial is testing

VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)Looking for participantsNCT06974786
What this trial is testing

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)
SCRI Development Innovations, LLC 100
Large-scale testing (Phase 3)Not Yet RecruitingNCT05558319
What this trial is testing

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

Who this might be right for
Newly Diagnosed Multiple Myeloma
PETHEMA Foundation 480
Testing effectiveness (Phase 2)Study completedNCT02685826
What this trial is testing

Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 56
Testing effectiveness (Phase 2)UnknownNCT00378755
What this trial is testing

Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

Who this might be right for
Multiple Myeloma
Korean Multiple Myeloma Working Party 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT04052880
What this trial is testing

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Who this might be right for
Newly Diagnosed Multiple Myeloma
Larysa Sanchez 17
Not applicableLooking for participantsNCT06099912
What this trial is testing

Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM

Who this might be right for
Multiple MyelomaFrailty
FengYan Jin 131
Testing effectiveness (Phase 2)Looking for participantsNCT05828511
What this trial is testing

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Who this might be right for
Multiple Myeloma
Regeneron Pharmaceuticals 149
Testing effectiveness (Phase 2)Active Not RecruitingNCT03989414
What this trial is testing

Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 424
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07247097
What this trial is testing

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple MyelomaTransplant Ineligible+1 more
Massachusetts General Hospital 160
Load More Results